Table 1.
Magnitude of the MCMV-specific CD8+ T-cell response in mice aged 18 months with or without 12 months of valaciclovir treatment
| Epitope | IFN-γ (% CD8)a |
% reductionb | |
|---|---|---|---|
| MCMV−AV | MCMV+AV | ||
| M38 | 4.87 (±1.45) | 1.21 (±0.39) | 75.15 |
| M45 | 4.88 (±1.46) | 1.35 (±0.41) | 72.40 |
| M57 | 1.59 (±1.15) | 0.32 (±0.13) | 80.03 |
| m139 | 2.84 (±1.24) | 0.74 (±0.37) | 73.05 |
| IE3 | 9.87 (±1.88) | 1.62 (±0.43) | 83.61 |
| Total | 23.95 (±4.48) | 5.23 (±1.11) | 78.16 |
a
Results are shown as the mean of the percentage of IFN-γ-secreting CD8+ T cells against MCMV-immunodominant peptides (±SEM).
b
Percent reduction observed between MCMV−AV–treated (n = 9) and MCMV+AV–treated (n = 11) mice. Data are combined from two independent experiments.